Adverum halt raises more gene therapy questions
A serious adverse event puts ADVM-022’s future in doubt, and it could hurt other eye disease gene therapy players too.
What pandemic? Biotech floats break records
After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.
Biopharma venture investors shrug off Covid-19
First-quarter venture investments barely register the pandemic - huge cash reserves should protect funding for biotech start-ups this year.
Another venture funding surge sets up a strong 2018
Cell and gene therapy companies dominate the first quarter, but companies outside these fashionable areas are finding it harder to charm VCs.